Business
GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising
PARIS, March 18, 2026--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/676d420d5634a554b4fccb3f6a313ee6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hJULbg3S32YkysuJ1q0JXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/676d420d5634a554b4fccb3f6a313ee6","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, March 18, 2026--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 1,694,715.5256 fundraising (the "Fundraising").","length":363,"tagName":"p"},{"type":"text","content":"The Fundraising resulted in the issuance of:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"14,153,928 ordinary shares (actions ordinaires) of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on March 12, 2026 (ISIN FR0013183985/SIGHT);","length":190,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"4,270,464 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 4,270,464 additional ordinary shares; and","length":150,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"18,424,392 warrants (the "Offered Investor Warrants") giving the right to subscribe to 9,212,196 additional ordinary shares.","length":134,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":474},{"type":"text","content":"The Offered Investor Warrants and the Offered Pre-Funded Warrants will not be admitted to trading on any venue.","length":111,"tagName":"p"},{"type":"text","content":"Risk factors","length":12,"tagName":"p"},{"type":"text","content":"The Company draws the atte...